enVVeno Medical (NVNO) director sells 4,900 shares under 10b5-1 plan

Rhea-AI Filing Summary

enVVeno Medical Corp director Francis Duhay reported selling 4,900 shares of common stock on December 11, 2025 at a weighted-average price of $0.3556 per share. The sale was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573. After this transaction, the director beneficially owns 92,544 shares of enVVeno Medical common stock. The filing states that the trade was completed under a Rule 10b5-1 trading plan that the reporting person adopted in June 2025, which is a pre-arranged plan for trading company stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duhay Francis

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		S(1)		4,900	D	$0.3556(2)	92,544	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

2. This transaction was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.

	/s/ Francis Duhay	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did enVVeno Medical Corp (NVNO) report?

The company reported that a director, Francis Duhay, sold 4,900 shares of enVVeno Medical Corp common stock on December 11, 2025.

What price did the NVNO director receive for the shares sold?

The shares were sold at a weighted-average price of $0.3556 per share, with individual trades executed between $0.3554 and $0.3573 during the day.

How many enVVeno Medical (NVNO) shares does the director own after the sale?

Following the reported transaction, the director beneficially owns 92,544 shares of enVVeno Medical Corp common stock.

Was the NVNO insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.

What type of SEC form discloses this NVNO insider transaction?

The transaction is disclosed on an SEC Form 4, which reports changes in beneficial ownership by company insiders such as directors and officers.

What is the relationship of the reporting person to enVVeno Medical Corp (NVNO)?

The reporting person is listed as a Director of enVVeno Medical Corp.